CNSP

CNS Pharmaceuticals, Inc. (CNSP) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. CNS Pharmaceuticals, Inc. is a biotechnology company that announced a new corporate strategy in March 2026 to pivot from a singular focus on glioblastoma multiforme. The new strategy involves developing innovative therapies for serious diseases and exploring out-licensing opportunities for legacy assets TPI 287 and Berubicin. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company reported no revenue for the period. Operating expenses totaled $4,975,205, comprised of $1,431,482 in General and Administrative (G&A) expenses and $3,543,723 in Research and Development (R&D) expenses.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $636,000 (14.8%) compared to Q1 2025, driven primarily by higher R&D costs and professional fees.
• Expense Growth: G&A expenses rose by ~$336,000 due to increases in legal/professional fees ($315,000) and insurance ($99,000), partially offset by lower compensation and travel costs. R&D expenses increased by ~$301,000 due to higher professional fees and headcount, though this was partially offset by declining costs for the Berubicin clinical trial.
• Cash Position: Cash and cash equivalents decreased significantly by approximately $4.25 million during the quarter, dropping from $7.2 million to $2.95 million.
• Equity Issuance: The company sold 178,933 shares of common stock via its ATM facility for net proceeds of approximately $501,000, compared to $9 million in proceeds from similar sales in Q1 2025.

Guidance, Outlook, and Risks

• Subsequent Financing: On May 5, 2026, the company completed a private placement financing raising gross proceeds of approximately $22.5 million. This included the sale of 650,000 common shares and pre-funded warrants for 9,143,479 shares. Management believes this alleviates substantial doubt regarding the company's ability to continue as a going concern.
• Strategic Pivot: The company is shifting focus to identify and secure rights to development-stage assets. Proceeds from the May financing will be used for this purpose.
• Internal Controls: Management concluded that internal controls over financial reporting were ineffective as of March 31, 2026. Material weaknesses were identified regarding a lack of segregation of duties and limited access to timely cost data from third-party Contract Research Organizations (CROs).
• Executive Changes: Significant leadership changes occurred in Q1 2026, including the resignation of the former CEO and the hiring of a new CEO (Rami Levin), CFO (Steve O'Loughlin), CMO (Lynne Kelley), and CTO (Eric Faulkner).
• Risk Factors: The company faces risks related to the need for additional capital, the success of clinical trials, regulatory approvals, and the ability to secure rights to new pipeline assets.

Investor Verification Checklist

• Capital Runway: Verify the utilization of the $22.5 million raised in May 2026 and confirm the timeline for the next potential capital raise.
• Internal Controls: Monitor progress in remediating the material weaknesses in internal controls, specifically regarding segregation of duties and CRO data reporting.
• Asset Pipeline: Assess the progress of the new corporate strategy to identify and in-license new development-stage assets.
• Executive Retention: Track the stability of the newly appointed executive team and the impact of recent leadership turnover on operations.
• Out-licensing Progress: Review updates on the potential out-licensing of legacy assets TPI 287 and Berubicin.